| Theme |
Early detection and prevention for cancer of dialysis patients |
| Title |
Helicobacter pylori infection and gastric cancer in dialysis patients |
| Author |
Chieko Hamada |
Division of Nephrology, Department of Internal Medicine, Juntendo University Faculty of Medicine |
| [ Summary ] |
Patients testing positive for Helicobacter pylori (H. pylori) infection exhibit a close relationship to gastric cancer. Eradication therapy is recommended to prevent the development of gastric cancer. The prevalence of H. pylori infection decreases over dialysis periods. However, risk of development into gastric cancer is comparable to that observed in healthy subjects. Therefore, H. pylori infection should also be treated in dialysis patients. The standard H. pylori infection eradication therapy for dialysis patients is PPI+CAM+AMPC+metronidazole. The treatment periods extend from seven days to three weeks. Serum and urinary antibody tests are conducted more than six months after treatment. Urea breath test (UBT) and stool antigen studyies are efficacious to judge of the effects of eradication treatments. |